Avanos Medical, Inc.

Good morning, ladies and gentlemen. Welcome to the Avanos fourth quarter 2024 earnings call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, February 26, 2025. I would now like to turn the conference over to Mr. Scott Gullivan, Senior Vice President of Strategy and Corporate Development.

Please go ahead. Good morning, everyone, and thanks for joining us.

It's my pleasure to welcome you to Avanos 2024 fourth quarter and full year earnings conference call. Presenting today will be Michael Greiner, interim CEO. Michael will review our fourth quarter and full year results, the current business environment, as well as provide an update on our transformation efforts. Additionally, Michael will provide our 2025 planning assumptions. We will finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, avanos.com. As a reminder, our comments today contain forward-looking statements related to the company, our expected performance, current economic conditions, and our industry. No assurance can be given as to future financial results. Actual results could differ materially from those in the forward-looking statements. For more information about forward-looking statements and the risk factors that could influence future results, please see today's press release and the risk factors described in our filings with the SEC. Additionally, we'll be referring to adjusted results and outlook. The press release has information on these adjustments and reconciliations to comparable gap financial measures. Now, I'll turn the call over to Michael.